Stig Hansen is the founder of Kimia Therapeutics. Kimia Therapeutics has raised $55M in total funding. Latest round: Series A. Based in San Francisco, CA.
Stig K. Hansen is the Co-founder, President, and CEO of Kimia Therapeutics, a biotech company founded in 2023 to focus on metabolic diseases as a spin-off from Carmot Therapeutics. In January 2024, Hansen's previous company, Carmot Therapeutics, was acquired by Roche for up to $3.1 billion, marking one of the largest biotech exits in recent years. Under his leadership, Kimia closed a $55 million Series A round in December 2023 to scale its ATLAS platform.
Full founder directory · Investor directory · Company funding database · Fundraising library